ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Vaccitech Doses First Patient in HBV002 for Chronic HBV americanpharmaceuticalreview
February 04, 2021Vaccitech announced the dosing of the first patient in HBV002. HBV002 is a Phase 1b/2a clinical trial designed to evaluate the safety and preliminary efficacy of VTP-300 both with and without a low-dose anti-PD-1 antibody in patients with CHB infection.
Pharma Sources Insight July 2025
